Biomedical application of chitosan-based nanoscale delivery systems: Potential usefulness in siRNA delivery for cancer therapy
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články, přehledy
PubMed
33712155
DOI
10.1016/j.carbpol.2021.117809
PII: S0144-8617(21)00196-X
Knihovny.cz E-zdroje
- Klíčová slova
- Cancer therapy, Chitosan, Gene delivery, Nanoparticle, Small interfering RNA (siRNA),
- MeSH
- antitumorózní látky chemie farmakologie terapeutické užití MeSH
- chemorezistence účinky léků MeSH
- chitosan chemie MeSH
- lidé MeSH
- malá interferující RNA chemie terapeutické užití MeSH
- nádory farmakoterapie patologie terapie MeSH
- nanočástice chemie MeSH
- nosiče léků chemie MeSH
- umlčování genů MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- antitumorózní látky MeSH
- chitosan MeSH
- malá interferující RNA MeSH
- nosiče léků MeSH
Gene therapy is an emerging and promising strategy in cancer therapy where small interfering RNA (siRNA) system has been deployed for down-regulation of targeted gene and subsequent inhibition in cancer progression; some issues with siRNA, however, linger namely, its off-targeting property and degradation by enzymes. Nanoparticles can be applied for the encapsulation of siRNA thus enhancing its efficacy in gene silencing where chitosan (CS), a linear alkaline polysaccharide derived from chitin, with superb properties such as biodegradability, biocompatibility, stability and solubility, can play a vital role. Herein, the potential of CS nanoparticles has been discussed for the delivery of siRNA in cancer therapy; proliferation, metastasis and chemoresistance are suppressed by siRNA-loaded CS nanoparticles, especially the usage of pH-sensitive CS nanoparticles. CS nanoparticles can provide a platform for the co-delivery of siRNA and anti-tumor agents with their enhanced stability via chemical modifications. As pre-clinical experiments are in agreement with potential of CS-based nanoparticles for siRNA delivery, and these carriers possess biocompatibiliy and are safe, further studies can focus on evaluating their utilization in cancer patients.
Centre for Materials Interface Istituto Italiano di Tecnologia Pontedera 56025 Pisa Italy
Sabanci University Nanotechnology Research and Application Center Tuzla 34956 Istanbul Turkey
Young Researchers and Elite Club Tehran Medical Sciences Islamic Azad University Tehran Iran
Citace poskytuje Crossref.org
Gene Editing-Based Technologies for Beta-hemoglobinopathies Treatment
